<DOC>
	<DOCNO>NCT00663910</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue laboratory patient nonmelanoma skin cancer treat topical aminolevulinic acid may help doctor predict patient respond photodynamic therapy . PURPOSE : This clinical trial study topical aminolevulinic acid patient nonmelanoma skin cancer .</brief_summary>
	<brief_title>Topical Aminolevulinic Acid Patients With Nonmelanoma Skin Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate distribution depth protoporphyrin IX ( PpIX ) within different type nonmelanoma skin cancer topical aminolevulinic acid ( ALA ) administration . - To obtain vivo measurement ALA-induced PpIX formation within different zone tumor measure fluorescence detection method . - To correlate level PpIX fluorescence detect non-invasive optical measurement morphological characteristic tumor . - To establish skin cancer tissue bank . OUTLINE : Topical aminolevulinic acid ( ALA ) apply center tumor surface . Patients undergo punch tumor biopsy area ALA apply follow surgery remove tumor . Tissue sample assess protoporphyrin ( PpIX ) level fluorescence confocal microscopy hyperspectral imaging . Excess tumor tissue may store skin cancer tissue bank . Surface measurement ( total 5 surface site ) PpIX fluorescence take baseline 2 hour ALA application use optical fiber-based hand-held dosimeter .</detailed_description>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Must least 1 biopsyproven nonmelanoma skin cancer minimum diameter 4 mm No tumor locate eyelid , distal nose , cartilaginous portion ear , lip PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known hypersensitivity aminolevulinic acid component medication PRIOR CONCURRENT THERAPY : Concurrent immunosuppressive chemotherapeutic medication allow Concurrent corticosteroid ( take mouth large dos take inhaler ) allow Concurrent systemic retinoids ( e.g. , isotretinoin , acitretin , bexarotene , alitretinoin ) vitamin A allowed Other concurrent medication may affect epidermal growth differentiation ( e.g. , antiEGFR monoclonal antibody ) allow No concurrent participation another clinical trial No concurrent topical treatment target tumor nonmelanoma skin cancer No concurrent medical therapy radiotherapy cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>basal cell carcinoma skin</keyword>
	<keyword>squamous cell carcinoma skin</keyword>
	<keyword>recurrent skin cancer</keyword>
</DOC>